Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

751
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
751
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

3.8K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.8K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.7K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.5K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.

The New England journal of medicine·2017
Same author

Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms.

Nature genetics·2017
Same author

Lack of MTTP Activity in Pluripotent Stem Cell-Derived Hepatocytes and Cardiomyocytes Abolishes apoB Secretion and Increases Cell Stress.

Cell reports·2017
Same author

Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease.

Circulation research·2017
Same author

Hepatic metal ion transporter ZIP8 regulates manganese homeostasis and manganese-dependent enzyme activity.

The Journal of clinical investigation·2017
Same author

Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis.

The Journal of biological chemistry·2017

関連する実験動画

Updated: Apr 25, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.1K

HDLと心血管疾患について

Daniel J Rader1, G Kees Hovingh2

  • 1Department of Medicine and Department of Genetics, Institute for Translational Medicine and Therapeutics, and Cardiovascular Institute, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA.

Lancet (London, England)
|August 19, 2014
PubMed
まとめ

高密度脂質タンパク質 (HDL) コレステロールは,心臓病のリスクの低下に関連していますが,動脈硬化症における直接的な因果的な役割は不明です. 現在進行中の研究と薬の開発は,HDLを明確にすることを目的としています.

科学分野:

  • 心血管科学 心血管科学
  • 脂質代謝についてです.
  • 動脈硬化症の研究研究

背景:

  • 高密度脂質タンパク質 (HDL) コレステロールは,冠動脈疾患 (CHD) のリスクと逆に関連しています.
  • HDLの動脈保護特性についてはよく知られているが,動脈硬化症におけるその因果的な役割については議論されている.
  • HDL仮説に対する懐疑論は,ヒトの遺伝学と臨床試験の結果から生じている.

研究 の 目的:

  • HDLと動脈硬化症の関係に関する現在の理解を評価する.
  • HDLを標的とする治療における最近の発見と進行中の研究の影響を議論する.
  • 心血管疾患の予防におけるHDL調節薬の可能性を評価する.

主な方法:

  • 人間の遺伝学の研究のレビュー.
  • HDL上昇療法に関する臨床試験データの分析.
  • HDL機能を標的とした新興の治療戦略の検討.

主要な成果:

  • 臨床試験の不一致の結果は,HDLと動脈硬化症の間の直接的な因果関係に疑問を投げかけています.
  • 不確実性にもかかわらず,HDLを標的とした新しい治療的介入は,臨床開発を通じて進展しています.

さらに関連する動画

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

1.2K

関連する実験動画

Last Updated: Apr 25, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.1K
Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test
10:21

Evaluation of Hydration Status by Bioelectrical Impedance Vector Analysis in Patients with Ischemic Heart Disease Undergoing Exercise Stress Test

Published on: September 22, 2023

1.2K
  • コレステリルエステル転移タンパク質 (CETP) 阻害剤は,開発後期段階にある.
  • 結論:

    • HDLを標的とする治療が冠動脈疾患に与える決定的な影響については,まだ決定されていない.
    • 心血管の健康におけるHDLの複雑な役割を明らかにするために,さらなる研究が必要です.
    • 逆コレステロール輸送を含むHDL機能を強化する薬剤の開発は,将来の心血管リスク管理に希望を示しています.